Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Iradimed's 3870 ramp supports full-year guidance; dividend maintained

Jul 31, 2026, 8:18 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive earnings trajectory, strategic product ramp (3870) with high-margin potential, and reaffirmed guidance reduce downside risk; dividend adds modest yield, supporting near-term upside.

AI summary

What happened, with direct paths to the underlying reporting

Iradimed reported Q2 2026 revenue of $20.5 million with GAAP EPS of $0.41 and non-GAAP EPS of $0.46. The company highlighted the 3870 MRI-compatible IV pump ramp and record domestic monitor bookings, signaling accelerating mix shifts and potential margin gains in H2. Guidance for 2026 remains intact at $91–96 million in revenue with $1.90–2.05 GAAP EPS and $2.09–2.24 non-GAAP EPS.

Q2 2026 revenue $20.5M, up 0.5% YoY; GAAP EPS $0.41, non-GAAP $0.46.
3870 MRI-compatible IV pump ramp underway; initial shipments met plan; margin uplift expected H2.
Domestic monitor bookings hit a record; over 70% of pump orders are quad-stack.
Full-year 2026 guidance reaffirmed: revenue $91-96M; GAAP EPS $1.90-2.05; non-GAAP $2.09-2.24.
Quarterly dividend declared at $0.20 per share; payable Aug 28, 2026.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.